Biofrontera Drug Patent Portfolio
Biofrontera owns 1 orange book drug protected by 4 US patents Given below is the list of Biofrontera's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12280146 | Nanoemulsion without propylene glycol | 08 Dec, 2043 | Active |
| US11235169 | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device | 15 Oct, 2040 | Active |
| US11540981 | Nanoemulsion formulation with improved stability and cell penetration | 07 Feb, 2028 | Active |
| US6559183 | Nano-emulsion of 5-aminolevulinic acid | 12 Nov, 2019 | Expired |
Latest Legal Activities on Biofrontera's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biofrontera.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 21 Mar, 2024 | US11540981 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11540981 |
| Mail-Petition Decision - Denied | 19 Mar, 2024 | US11540981 |
| Petition Decision - Denied | 18 Mar, 2024 | US11540981 |
| O.P. Petition Decision | 18 Mar, 2024 | US11540981 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Dec, 2023 | US11540981 |
| Petition Entered | 27 Apr, 2023 | US11540981 |
|
Recordation of Patent Grant Mailed
Critical
| 03 Jan, 2023 | US11540981 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 03 Jan, 2023 | US11540981 |
|
Email Notification
Critical
| 15 Dec, 2022 | US11540981 |
|
Issue Notification Mailed
Critical
| 14 Dec, 2022 | US11540981 |
|
Application Is Considered Ready for Issue
Critical
| 02 Dec, 2022 | US11540981 |
| Dispatch to FDC | 02 Dec, 2022 | US11540981 |
|
Issue Fee Payment Verified
Critical
| 30 Nov, 2022 | US11540981 |
|
Issue Fee Payment Received
Critical
| 30 Nov, 2022 | US11540981 |
Biofrontera's Family Patents
Biofrontera Drug List
Given below is the complete list of Biofrontera's drugs and the patents protecting them.
1. Ameluz
Ameluz is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12280146 | Nanoemulsion without propylene glycol |
08 Dec, 2043
(18 years from now)
| Active |
| US11235169 | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
15 Oct, 2040
(14 years from now)
| Active |
| US11540981 | Nanoemulsion formulation with improved stability and cell penetration |
07 Feb, 2028
(2 years from now)
| Active |
| US6559183 | Nano-emulsion of 5-aminolevulinic acid |
12 Nov, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ameluz's drug page